Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04614467
PHASE2

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Sponsor: Lisata Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.

Official title: A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

34

Start Date

2020-10-29

Completion Date

2022-09-28

Last Updated

2026-05-04

Healthy Volunteers

No

Interventions

BIOLOGICAL

CLBS16

GCSF-mobilized autologous CD34+ cells

BIOLOGICAL

Placebo

isotonic solution (no CD34+ cells)

Locations (7)

Cedars-Sinai Medical Center

Los Angeles, California, United States

University of Florida - College of Medicine/ div of Cardiovascular Medicine

Gainesville, Florida, United States

Memorial Regional Hospital

Hollywood, Florida, United States

Emory University Hospital

Atlanta, Georgia, United States

Minneapolis Heart Institute at Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

The Christ Hospital

Cincinnati, Ohio, United States